Status:
ACTIVE_NOT_RECRUITING
Impact of Fatty Liver on Hepatitis B Therapy
Lead Sponsor:
Tianjin Second People's Hospital
Conditions:
Fatty Liver Disease
Chronic Hepatitis B
Eligibility:
All Genders
18-75 years
Brief Summary
The primary goal of treating chronic hepatitis B(CHB) is to achieve maximal suppression of HBV replication, thereby reducing hepatocyte inflammation, necrosis, and liver fibrosis. Among various treatm...
Detailed Description
Chronic hepatitis B (CHB) remains a serious threat to people's health. As of 2019, approximately 296 million people (3.9% of the world's population) were infected with the HBV virus. In the treatment ...
Eligibility Criteria
Inclusion
- Aged ≥18 and ≤75 years old, regardless of gender;
- The patient had a positive hepatitis B marker and met the criteria for current hepatitis B virus infection (hepatitis B combined with fatty liver group);
- Liver pathology indicated fatty liver (hepatitis B combined with fatty liver group);
- All patients have complete medical history, B-ultrasound, FibroSan, hepatitis B five items, liver function and other laboratory test data.
Exclusion
- Aged \<18 or \>75 years old;
- Patients diagnosed with or previously diagnosed with HCC;
- Those who are co-infected with other hepatitis viruses (HAV, HCV, HDV, HEV) or HIV or syphilis;
- The follow-up data of patients are seriously missing.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06535048
Start Date
January 1 2015
End Date
August 31 2024
Last Update
August 2 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.